Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine

Clinical Cancer Research

Volumn 13, Issue 15, 2007, Pages 4503-4510

  Gordon, Nancy ^a   Koshkina, Nadezhda V ^a   Jia, Shu Fang ^a   Khanna, Chand ^b   Mendoza, Arnulfo ^b   Worth, Laura L ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; GEMCITABINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LUNG CLEARANCE; LUNG ENDOTHELIUM; LUNG METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

AEROSOLS; ANIMALS; ANTIGENS, CD95; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; DEOXYCYTIDINE; FLOW CYTOMETRY; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; OSTEOSARCOMA; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 34547686124     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0313     Document Type: Article

References (31)

1. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6.
2. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-6.
3. Goorin AM, Shuster J, Baker A, Horowitz ME, Meyer WH, Link MP. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol 1991;9:600-5.
4. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997;33:1725-31.
5. Bruheim S, Bruland OS, Breistol K, Maelandsmo GM, Fodstad O. Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res 2004;10:133-41.
6. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001;19:292-315.
7. Owen-Schaub LB, van Golen KL, Hill LL, Price JE. Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 1998;188:1717-23.
8. Moller P, Koretz K, Leithauser F, et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994;57:371-7.
9. Hill LL, Ouhtit A, Loughlin SM , et al. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science 1999;285:898-900.
10. Zornig M, Grzeschiczek A, Kowalski MB, Hartmann KU, Möröy T. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 1995;10:2397-401.
11. Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LL. Fas and Fas ligand interactions in malignant disease. Int J Oncol 2000;17:5-12.
12. Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 1999;17:501-6.
13. Worth LL, Lafleur EA, Jia SF, Kleinerman ES. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 2002;9:823-7.
14. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 2000;18:261-71.
15. Khanna C, Khan J, Nguyen P, et al. Metastasis-associated differences ingene expression in a murine model of osteosarcoma. Cancer Res 2001;61:3750-9.
16. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-6.
17. Zhang J, Winoto A. A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis. Mol Cell Biol 1996;16:2756-63.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
19. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 2005;116:458-63.
20. Koshkina NV, Kleinerman ES, Waidrep C, et al. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 2000;6:2876-80.
21. Lafleur EA, Jia SF, Worth LL, et al. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res 2001;61:4066-71.
22. Gordon N, Arndt CA, Hawkins DS, et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005;27:611-5.
23. Ivanova ST, Dazri AW, Peck D. The Fas/FasL system potentiates invasive phenotype via transcription factor dependent upregulation of metalloproteases [abstract 3453]. Proceedings of the 97th American Association for Cancer Research Annual Meeting 2006.
24. Lafleur EA, Koshkina NV, Stewart J, et al. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 2004;10:8114-9.
25. Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB. Death receptor-induced cell death in prostate cancer. J Cell Biochem 2004;91:70-99.
26. Koshkina NV, Kleinerman ES. The Fas pathway contributes to the metastatic potential of osteosarcoma to the lungs [abstract 738]. Proceedings of the 97th American Association of Cancer Research Annual Meeting 2006.
27. Bjornland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM. Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res 2005;127:151-6.
28. Ferrari C, Benassi S, Ponticelli F, et al. Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years. Acta Orthop Scand 2004;75:487-91.
29. Himelstein BP, Asada N, Carlton MR, Collins MH. Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol 1998;31:471-4.
30. Kawashima A, Nakanishi I, Tsuchiya H, Roessner A, Obata K, Okada Y. Expression of matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) induced by tumour necrosis factor α correlates with metastatic ability in a human osteosarcoma cell line. Virchows Arch 1994;424:547-52.
31. Kido A, Tsutsumi M, Iki K, et al. Overexpression of matrix metalloproteinase (MMP)-9 correlates with metastatic potency of spontaneous and 4-hydroxyaminoquinoline 1-oxide (4-HAQO)-induced transplantable osteosarcomas in rats. Cancer Lett 1999;137:209-16.